Last reviewed · How we verify
Transdermal glyceryl trinitrate patch
Transdermal glyceryl trinitrate patch works by releasing nitric oxide, which causes vasodilation and reduces blood pressure.
Transdermal glyceryl trinitrate patch works by releasing nitric oxide, which causes vasodilation and reduces blood pressure. Used for Angina pectoris, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Transdermal glyceryl trinitrate patch |
|---|---|
| Also known as | Local ward stock to be used. |
| Sponsor | University of Nottingham |
| Drug class | Nitrate |
| Target | Guanylate cyclase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The nitric oxide released by the patch activates guanylate cyclase, leading to increased levels of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This results in relaxation of vascular smooth muscle and subsequent vasodilation, which reduces blood pressure and myocardial oxygen demand.
Approved indications
- Angina pectoris
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Dizziness
- Hypotension
Key clinical trials
- Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis (EARLY_PHASE1)
- Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. (NA)
- Flushing Reduction Associated With Nitrates (PHASE2)
- GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy (PHASE2)
- Nitrate Use to Obtain Radial Spasm Embarrassment (NURSE - TTS Trial) (PHASE3)
- Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer (PHASE1)
- Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer (PHASE2)
- Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal glyceryl trinitrate patch CI brief — competitive landscape report
- Transdermal glyceryl trinitrate patch updates RSS · CI watch RSS
- University of Nottingham portfolio CI